

-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

KARA MITCHELL 18-Mar-1988 Female

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



4017792

COMPLETE MICROBIOME MAPPING

General Macro	scopic Description	
	Result	Markers
Stool Colour	Brown	Colour - Brown is the colour of normal stool. Other colours may indicate abnormal gut health.
Stool Form	Semi-formed	Form -Sample form is categorised using the Bristol stool chart. A comment on stool appearance can be found in the comments section.
Mucous	Not Detected	Mucous - Mucous production may indicate the presence of an infection and/or inflammation.
Occult Blood	Negative	Blood (Macro) - The presence of blood in the stool may be the result of several causes besides colorectal bleeding, including hemorrhoids or gastrointestinal infection.

Short Chain Fatty Acids	Result	Range	Units	
Methodology: GC/MS				
Short Chain Fatty Acids, Beneficial	38.8	> 13.6	umol/g	•
Butyrate	31.5	10.8 - 33.5	%	
Acetate	45.2	44.5 - 72.4	%	•
Propionate	19.4	0.0 - 32.0	%	•
Valerate	3.9	0.5 - 7.0	%	

GIT Functional Markers	Result	Range	Units	
Methodology: FEIA, EIA, CLIA, pH electrode				
Calprotectin.	18.0	0.0 - 50.0	ug/g	•
Pancreatic Elastase	>800.0	> 200.0	ug/g	
Secretory (slgA)	703.5	510.0 - 2040	.0 ng/mL	
Zonulin	37.2	0.0 - 107.0	ng/mL	
Beta glucuronidase	4024.3	368.0 - 6266	.0 U/g	
Steatocrit	5.0	0.0 - 10.0	%	•
a-Transglutaminase IgA	33.0	0.0 - 100.0	units/L	
pH	6.8	6.3 - 7.7		•

Microbiome Mapping Summary

Parasites & Worms	Bacteria & Viruses	Fungi and Yeasts
	Streptococcus salivarius.	
Key Phyla Microbiota Firmicutes:Bacteroidetes Ratio	2.21 *H < 1.00 RATIO	

Relative Commensal Abundance of the 6 Phyla groups can be found on page 5 of this report



-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

Strongyloides spp, Roundworm

KARA MITCHELL 18-Mar-1988 Female

Taenia species, Tapeworm

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



404	
401	1192

Not Detected

Parasites and Worms.	Result	Range	Units		
Parasitic Organisms					
Cryptosporidium species	<dl< th=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Entamoeba histolytica.	<dl< th=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Giardia intestinalis	<dl< th=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Blastocystis hominis.	<dl< th=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Dientamoeba fragilis.	<dl< th=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Endolimax nana	<dl< th=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Entamoeba coli.	<dl< th=""><td>< 5.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 5.0	x10^5 org/g		
Pentatrichomonas hominis	<dl< th=""><td>< 1.0</td><td>x10^5 org/g</td><td></td><td></td></dl<>	< 1.0	x10^5 org/g		
Worms					
Ancylostoma duodenale, Roundworr	n Not Dete	ected			
Ascaris lumbricoides, Roundworm	Not Dete	ected	Necator an	nericanus, Hookworm	Not Detected
Trichuris trichiura, Whipworm	Not Dete	ected	Enterobius	vermicularis,Pinworm	Not Detected
Enterocytozoon spp	Not Dete	ected		ois spp, Tapeworm	Not Detected

Comment: Not Detected results indicate the absence of detectable DNA in the sample for the worms reported. NOTE: Reflex testing is performed on clinically indicated samples

Not Detected

pportunistic Bacteria/Overgrowth	Result	Range	Units	
Bacillus species.	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th><th></th></dl<>	< 1.00	x10^4 CFU/g	
Enterococcus faecalis	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Enterococcus faecium	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Morganella species	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Pseudomonas species	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 1.00	x10^4 CFU/g	
Pseudomonas aeruginosa.	<dl< th=""><td>< 3.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 3.00	x10^4 CFU/g	
Staphylococcus species	<dl< th=""><td>< 1.00</td><td>x10^3 CFU/g</td><td></td></dl<>	< 1.00	x10^3 CFU/g	
Staphylococcus aureus	<dl< th=""><td>< 5.00</td><td>x10^3 CFU/g</td><td></td></dl<>	< 5.00	x10^3 CFU/g	
Streptococcus agalactiae.	<dl< th=""><td>< 3.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 3.00	x10^4 CFU/g	
Streptococcus anginosus.	<dl< th=""><td>< 1.00</td><td>x10^6 CFU/g</td><td></td></dl<>	< 1.00	x10^6 CFU/g	
Streptococcus mutans.	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 1.00	x10^4 CFU/g	
Streptococcus oralis.	0.74	< 1.00	x10^6 CFU/g	
Streptococcus salivarius.	<i>6.7</i> 7 *H	< 5.00	x10^6 CFU/g	
Methanobrevibacter smithii	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Desulfovibrio piger	<dl< th=""><td>< 18.00</td><td>x10^6 CFU/g</td><td></td></dl<>	< 18.00	x10^6 CFU/g	
Enterobacter cloacae complex.	<dl< th=""><td>< 5.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 5.00	x10^5 CFU/g	
otential Autoimmune Triggers				
Citrobacter species.	<dl< th=""><td>< 5.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 5.00	x10^4 CFU/g	
Citrobacter freundii.	<dl< th=""><td>< 5.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 5.00	x10^4 CFU/g	
Klebsiella species	<dl< th=""><td>< 5.00</td><td>x10^3 CFU/g</td><td></td></dl<>	< 5.00	x10^3 CFU/g	
Klebsiella pneumoniae.	<dl< th=""><th>< 5.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 5.00	x10^5 CFU/g	
Prevotella copri	<dl< th=""><td>< 1.00</td><td>x10^9 CFU/g</td><td></td></dl<>	< 1.00	x10^9 CFU/g	
Proteus species	<dl< th=""><td>< 5.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 5.00	x10^5 CFU/g	
Proteus mirabilis.	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 1.00	x10^4 CFU/g	
Fusobacterium species	1.54	< 10.00	x10^4 CFU/g	



-.JAYNE ELDER **SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450**

KARA MITCHELL Female 18-Mar-1988

1 MORELIA WAY **WOOMBAH NSW 2469**

LAB ID: 4017792 UR NO.: 6644865 Collection Date : 26-Aug-2024 **Received Date:** 28-Aug-2024



ycology	Result	Range	Units	
Candida dubliniensis.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
Candida glabrata.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida intermedia.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida krusei.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida lambica.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida lusitaniae.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida parapsilosis.	0.18	< 1.00	x10^5 CFU/g	
Candida albicans.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida famata.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida keyfr.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Candida lipolytica.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Geotrichum species.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Rhodotorula species.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Saccharomyces cerevisiae:	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
cterial Pathogens	Result	Range	Units	
Aeromonas hydrophila.	<dl< th=""><th>< 1.00</th><th>x10^3 CFU/g</th><th></th></dl<>	< 1.00	x10^3 CFU/g	
Campylobacter species.	<dl< th=""><th>< 1.00</th><th>x10^5 CFU/g</th><th></th></dl<>	< 1.00	x10^5 CFU/g	
C. difficile, Toxin A	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 1.00	x10^4 CFU/g	
C. difficile, Toxin B	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 1.00	x10^4 CFU/g	
Enterohemorrhagic E. coli	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Enteroinvasive E. coli/Shigella	<dl< th=""><td>< 1.00</td><td>x10^3 CFU/g</td><td></td></dl<>	< 1.00	x10^3 CFU/g	
Enterotoxigenic E. coli LT/ST	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Shiga-like Toxin E. coli stx1	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 1.00	x10^4 CFU/g	
Shiga-like Toxin E. coli stx2	<dl< th=""><td>< 1.00</td><td>x10^4 CFU/g</td><td></td></dl<>	< 1.00	x10^4 CFU/g	
Salmonella species.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Vibrio species.	<dl< th=""><th>< 1.00</th><th>x10^4 CFU/g</th><th></th></dl<>	< 1.00	x10^4 CFU/g	
Yersinia species.	<dl< th=""><td>< 1.00</td><td>x10^5 CFU/g</td><td></td></dl<>	< 1.00	x10^5 CFU/g	
Helicobacter pylori	<dl< th=""><td>< 1.0</td><td>x10^3 CFU/g</td><td></td></dl<>	< 1.0	x10^3 CFU/g	
Comment: Helico Pylori virulenc	ce factors v	vill be liste	ed below if detected POSITIVE	
H.pylori Virulence Factor, babA	Not Dete	cted	H.pylori Virulence Factor, cagA	Not Detected
H.pylori Virulence Factor, dupA	Not Dete	cted	H.pylori Virulence Factor, iceA	Not Detected
H.pylori Virulence Factor, oipA	Not Dete	cted	H.pylori Virulence Factor, vacA	Not Detected
H.pylori Virulence Factor, virB	Not Dete	cted	H.pylori Virulence Factor, virD	Not Detected
ral Pathogens	Result	Range	Units	

GIT Functional markers performed by GCMS,EIA,FEIA.

Adenovirus 40/41

Sapovirus (I,II,IV,V)

Astrovirus (hAstro)

Norovirus GI/II

Rotavirus A

Bacteriology, Virology, Fungi, Parasites & Worms performed by PCR, qPCR. <dl = result below detectable limit. *H = Result greater than the reference range. *L = Result less than the reference range

Not Detected

Not Detected

Not Detected

Not Detected

Not Detected



-.JAYNE ELDER **SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450**

KARA MITCHELL 18-Mar-1988 **Female**

1 MORELIA WAY **WOOMBAH NSW 2469**

LAB ID: 4017792 UR NO.: 6644865 Collection Date: 26-Aug-2024 Received Date: 28-Aug-2024



Normal Bacterial GUT Flora	Result Range	Units	
Bacteroides fragilis	<d/*L 1.6 - 250.0</d	x10^5 CFU/g	
Bifidobacterium adolescentis	19.8 4.6 - 1000.0	x10^5 CFU/g	
Bifidobacterium bifidum.	<dl*l -="" 1000.0<="" 4.6="" th=""><td>x10^6 CFU/g ●</td><td></td></dl*l>	x10^6 CFU/g ●	
Bifidobacterium breve.	<dl*l -="" 1000.0<="" 4.6="" th=""><td>x10^3 CFU/g ●</td><td></td></dl*l>	x10^3 CFU/g ●	
Bifidobacterium longum	9.0 4.6 - 1000.0	x10^4 CFU/g	
Enterococcus species	<dl*l -="" 1.9="" 2000.0<="" th=""><td>x10^3 CFU/g ●</td><td></td></dl*l>	x10^3 CFU/g ●	
Escherichia species	449.5 3.7 - 3800.0	x10^4 CFU/g	
Lactobacillus acidophilus.	<d/*L 1.7 - 500.0</d	x10^3 CFU/g ●	
Lactobacillus casei.	14.6 1.7 - 500.0	x10^3 CFU/g	•
Lactobacillus delbrueckii	450.1 1.7 - 500.0	x10^3 CFU/g	
Lactobacillus plantarum.	22.1 1.7 - 500.0	x10^3 CFU/g	
Lactobacillus rhamnosus	<d/*L 1.7 - 500.0</d	x10^3 CFU/g ●	
Lactobacillus salivarius	<d/*L 1.7 - 500.0</d	x10^3 CFU/g ●	
Clostridium species	140.0 *H 5.0 - 50.0	x10^7 CFU/g	
Oxalobacter formigenes	4.48 *L > 5.00	x10^6 CFU/g	
Akkermansia muciniphila	14.42 1.00 - 50.00	x10^7 CFU/g	
Faecalibacterium prausnitzii	639.5 200.0 - 3500.	0 x10^6 CFU/g	

Actions	plantarum HEAL9	. paracasel 8700:2	plantarum HEAL19	L. plantarum 6595	L. plantarum 299V	L. rhamnosus GG	. acidophilus LA02	nals subsp. lactis BS01	L. casei LC03	B. breve BR03	L. fermentum LF08	L. crispatus strains	nals subsp. lactis BA05	L. plantarum LP01	L. rhamnosus LR06	B. longum 04	L. fermentum LF16	L. salivarius LS01	B. breve B632	L. fermentum LF10	L. salivarius LS03	nelveticus Rosell-52	hamnosus Rosell-11	longums Rosell-75	Jardii CNCM 1-1079	S. thermophilus FP4
Intestinal epithelial barrier health				•	•	•			•	•								•				•	•		•	
Mucous membrane health				•		•																	•		•	
Normalisation of bowel movements					•	•	•	•		•				•								•				
Normalisation of bloating					•	•	•	•		•				•												
Normalisation of peristalsis					•	•	•	•		•				•											•	
Autoimmune immunomodulation	•	•	•		•	•																				
Inhibition of pathogenic overgrowth				•	•	•				•									•		•	•	•	•	•	
Inactivate microbial toxins																									•	
Increase infection resistance	•	•		•		•		•														•		•	•	
Th1/Th2 immune cell modulation						•				•								•	•			•	•			
Staphylococci inhibition										•								•								
Gut-brain axis support					•									•	•	•	•					•		•		
GABA production						•			•																	
Bone resorption inhibition	•	•	•																							
E. coli inhibition										•				•	•				•			•	•	•	•	
Oxalate degradation						•	•							•												



-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

KARA MITCHELL 18-Mar-1988 Female

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



4017792


Introduction:

Your gut microbiome is a collective name for the 40 trillion cells and up to 1000 microbial species that include bacteria, viruses, fungi, parasites, and archaea and reside in our gut. The number of gut bacterial cells is approximately equal to the total number of human cells in our body, so if we consider only cell counts, we are only about half human. In terms of gene counts, the microbiome contains about 200 times more genes than the human genome, making bacterial genes responsible for over 99% of our body's gene content! Of all the microbial communities in the human body, the gut microbiome is by far the most dense, diverse, and physiologically important ecosystem to our overall health.

Re	lative Commensal Abundanc	e Result	Range	Units
	Firmicutes Phylum	<i>68.260</i> *H	3.500 - 40.000	%
	Bacteroidetes Phylum	<i>30.839</i> *L	50.000 - 95.000	%
	Verrucomicrobia Phylum	0.484	0.000 - 2.400	%
	Proteobacteria Phylum	0.401	0.050 - 12.500	%
	Actinobacteria Phylum	0.015	0.001 - 4.818	%
	Euryarchaeota Phylum	0.000	0.000 - 0.010	%

Your Phyla:

Healthy Phyla:



References

NOTE: Relative abundance reference ranges have been based on a healthy population study.

King CH, et., al. (2019) Baseline human gut microbiota profile in healthy people and standard reporting template. PLoS One. 2019 Sep 11;14(9):e0206484.

Page 5 of 11 Complete Microbiome Map V2 Lab ID: 4017792 Patient Name: KARA MITCHELL Printed: 05/Sep/24 15:15



-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

KARA MITCHELL 18-Mar-1988 Female

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



4017792

Pathogen Summary:

Macroscopy Comment

BROWN coloured stool is considered normal in appearance.

Faecal Occult Blood Negative:

Faecal occult blood has not been detected in this specimen. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is recommended.

Metabolism Comment

In a healthy gut Short Chain Fatty Acids (SCFAs) exhibited in the following proportions; Butyrate, Acetate, Propionate (16%:60%:24%).

The primary SCFAs butyrate, propionate and acetate are produced by predominant commensal bacteria via fermentation of soluble dietary fibre and intestinal mucus glycans.

Key producers of SCFAs include Faecalibacterium prausnitzii, Akkermansia mucinphila, Bacteroides fragilis, Bifidobacterium, Clostridium and Lactobacillus Spp.

The SCFAs provide energy for intestinal cells and regulate the actions of specialised mucosal cells that produce anti-inflammatory and antimicrobial factors, mucins that constitute the mucus barriers, and gut active peptides that facilitate appetite regulation and euglycemia. Abnormal SCFAs may be associated with dysbiosis, intestinal barrier dysfunction and inflammatory conditions.



-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

KARA MITCHELL 18-Mar-1988 Female

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



4017792

GIT Markers Comment

PANCREATIC ELASTASE: Normal exocrine pancreatic function.

Pancreatic Elastase reflects trypsin, chymotrypsin, amylase and lipase activity.

This test is not affected by supplements of pancreatic enzymes.

Healthy individuals should be producing >500 ug/g of PE-1 under normal/healthy conditions.

PE-1 levels between 200 - 500 ug/g may indicate suboptimal production.

PE-1 levels <200 ug/g indicate clear inadequate production.

The clinician should therefore consider digestive enzyme supplementation if one or more of the following conditions is present: Loose watery stools, Undigested food in the stools, Post-prandial abdominal pain, Nausea or colicky abdominal pain, Gastroesophageal reflux symptoms, Bloating or food intolerance.

Testing performed by chemiluminescence immunosassay (CLIA).

CALPROTECTIN Normal:

Faecal calprotectin values <50 ug/g are not indicative of inflammation in the gastrointestinal tract. Subjects with low faecal calprotectin levels normally do not need to be further investigated by invasive procedures. In patients with strong clinical indications of intestinal inflammation, repeat testing may be useful.

Test performed by Phadia EliA Fluorescence enzyme immunoassay (FEIA).

SECRETORY IGA NORMAL:

Secretory IgA is within range.

Secretory IgA represents the first line of defence of the gastrointestinal mucosa and is central to the normal function of the gastrointestinal tract as an immune barrier. Review this level with other pathogenic bacteria and normal commensal flora. Lower levels within reference range should be interpreted clinically.

ZONULIN NORMAL:

Zonulin is a protein that modulates intestinal barrier function. This results is considered normal.

beta-GLUCORONIDASE NORMAL:

 $\ensuremath{\mathsf{B-Glucuronidase}}$ is considered normal and is within reference range.

Opportunistic Bacteria Comment

STREPTOCOCCUS SALIVARIUS ELEVATED:

PHYLUM: Firmicutes

DESCRIPTION:

Streptococcus salivarius is a Gram-positive bacterium primarily found in the oral and upper respiratory microbiomes but also present in the gut microbiome. It plays a protective role by producing bacteriocins (BLIS), which inhibit pathogens such as Streptococcus pyogenes. In the gut, S. salivarius contributes to maintaining a balanced microbial environment, supporting overall gut health and enhancing the immune system. Its ability to produce antimicrobial substances helps to prevent the overgrowth of harmful bacteria, promoting a healthy gut microbiome.

Page 7 of 11 Complete Microbiome Map V2 Lab ID: 4017792 Patient Name: KARA MITCHELL Printed: 05/Sep/24 15:15



-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

KARA MITCHELL 18-Mar-1988 Female

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



4017792

Phyla Microbiota Comment

FIRMICUTES (PHYLUM) ELEVATED:

DESCRIPTION:

Firmicutes are a phylum of diverse bacteria which are primarily grouped into classes, Bacilli, Clostridia, Erysipelotrichia and Negativicutes. They are found in various environments, including the intestinal tract, and the group includes some notable pathogens. Firmicutes are involved in energy resorption in the gut microbiome and levels may be affected by diet. Elevated levels and disturbance of gastrointestinal microbiome balance, particularly Firmicutes/Bacteroidetes ratio, have been associated with inflammation, obesity, diabetes and with a high sugar/ fat diet.

TREATMENT SUGGESTIONS: Consider using Bifidobacterium or Saccharomyces containing probiotics. It may also be suggested to optimise the patient diet. A lower fat diet may help to normalize Firmicutes levels.

FIRMICUTES/BACTEROIDETES RATIO ELEVATED:

Elevated Firmicutes/Bacteroidetes ratio is frequently cited in the scientific literature as a hallmark of obesity, metabolic syndrome, irritable bowel syndrome or diabetes risk. The ratio may also be used to evaluate commensal microbial balance.

The calculation provided in this report is made by the sum of abundance of Firmucutes tested divided by the sum of abundance Bacteroidetes. Reference ranges are based off internal cohort studies.

Treatment:

Balance commensal bacteria using the 4R Protocol which is located at the end of this test report. When firmicutes are high, consider using Bifidobacterium probiotics and Saccharomyces boulardii primarily. Lactobacillus spp. and Bacillus spp. (found in probiotics) can elevate firmicutes. It is further suggested to optimize the patient diet. A lower fat diet may assist to normalize the F/B ratio.

Page 8 of 11 Complete Microbiome Map V2 Lab ID: 4017792 Patient Name: KARA MITCHELL Printed: 05/Sep/24 15:15



-.JAYNE ELDER **SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450**

KARA MITCHELL **Female** 18-Mar-1988

1 MORELIA WAY **WOOMBAH NSW 2469**

LAB ID: 4017792 UR NO.: 6644865 Collection Date : 26-Aug-2024 **Received Date:** 28-Aug-2024



Normal Bacterial Flora Comment

BACTEROIDES FRAGILIS LOW:

PHYLUM: Bacteroidetes

DESCRIPTION: Bacteroides fragilis is an anaerobic, Gram-negative bacterium. It is part of the normal microbiota of the human colon and is generally commensal. Bacteroides fragilis plays an intricate role in the human colon and usually has a beneficial relationship with the host. Low Bacteroides fragilis levels have been associated with inflammatory bowel disease and Crohn's.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics and dietary modification.

BIFIDOBACTERIUM BIFIDUM LOW:

PHYLUM: Actinobacteria

Bifidobacterium bifidum is a Gram-positive, anaerobic bacterium integral to the human gut microbiota, especially in infants. It ferments a variety of carbohydrates, including human milk oligosaccharides, aiding in digestion, and promoting a healthy gut flora. B. bifidum produces short-chain fatty acids that lower gut pH and inhibit pathogenic bacteria while supporting intestinal cells. It also modulates the immune system, enhancing immune responses and reducing inflammation, and strengthens the intestinal barrier. Clinically, B. bifidum has shown promise in alleviating gastrointestinal disorders.

BIFIDOBACTERIUM BREVE LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium breve is a Gram-positive, anaerobic bacterium that is commonly found in the human gastrointestinal tract, particularly in the intestines of infants. B. breve is known for its ability to metabolise various carbohydrates, including human milk oligosaccharides, which is essential for the development of a healthy gut flora in newborns.

Studies demonstrate that B. breve exhibits several beneficial properties, including the production of short-chain fatty acids (SCFAs) such as acetate, which contribute to gut health by lowering pH and inhibiting the growth of pathogenic bacteria.

Additionally, B. breve may alleviate symptoms of irritable bowel syndrome (IBS) and improve symptoms of atopic dermatitis.

ENTEROCOCCUS SPECIES LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Enterococci are Gram-positive facultative anaerobic cocci commonly found in the environment, water, food, human skin, oral cavity and intestine. Strains belonging to the genus Enterococcus produce a wide variety of bacteriocins which are active against Gram-positive foodborne pathogens. Certain Enterococcus species have also been found to produce butyrate, a metabolic product that induces significant anti-inflammatory effects and contributes to intestine epithelial integrity. Low levels of enterococcus species may be associated with increased inflammation and susceptibility to foodborne pathogens. Review this with other beneficial flora.

TREATMENT SUGGESTIONS: Commensal probiotic cocktails are suggested to elevate colonization.

LACTOBACILLUS ACIDOPHILUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus acidophilus is a Gram-positive, rod-shaped, non-spore-forming bacterium commonly found in the human gut and fermented foods. It plays a key role in oxalate degradation, bowel normalisation and may assist patients with bloating.

TREATMENT SUGGESTIONS:

Consider probiotic supplementation containing L. acidophilus.

LACTOBACILLUS RHAMNOSUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus Rhamnosus is a Gram-positive anaerobic bacterium and is one of the most widely used probiotic strains, of which

Printed: 05/Sep/24 15:15 Page 9 of 11 Complete Microbiome Map V2 Lab ID: 4017792 Patient Name: KARA MITCHELL



-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

KARA MITCHELL 18-Mar-1988 Female

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



4017792

various health effects are well documented including the prevention and treatment of gastro-intestinal infections and diarrhea and even preventing certain allergic symptoms.

Decreased Lactobacillus rhamnosus colonisation has been shown to decrease gastro-intestinal health, increasing the risk of gastro-intestinal infections and diarrhea as well as extra-intestinal infections including oral and respiratory health. Studies have also revealed that chronic psychological stress and alcohol use may be associated with a decrease in Lactobacillus species, as well as antibiotic / medication use.

TREATMENT SUGGESTIONS: Treatment may involve the use of Lactobacillus containing probiotics and treatment of any intestinal infections.

LACTOBACILLUS SALIVARIUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus salivarius is a Gram-positive, rod-shaped, non-spore-forming bacterium predominantly found in the human oral cavity, gastrointestinal tract, and vagina. It plays a significant role in maintaining oral and gut health by producing lactic acid and bacteriocins, which inhibit the growth of pathogenic bacteria. L. salivarius enhances gut barrier function, modulates the immune system, and helps in the digestion of proteins and complex carbohydrates. It has been studied for its potential benefits in managing conditions such as irritable bowel syndrome (IBS), periodontal disease, and atopic dermatitis, highlighting its importance in promoting overall health and preventing infections.

TREATMENT SUGGESTIONS:

Consider L. salivarius as a probiotic strain which may improve intestinal permeability and immune response.

CLOSTRIDIUM SPECIES ELEVATED:

PHYLUM: Firmicutes

DESCRIPTION:

Clostridium is a genus of anaerobic, Gram-positive bacteria found in the environment and the intestinal tract. This genus includes several species and can utilize large amounts of nutrients that cannot be digested by host and produce short-chain fatty acids (SCFAs), which play a noticeable role in intestinal homeostasis. Colonisation of Clostridium species may be affected by diet (carbohydrate and protein in diet) and general health and may be protective against inflammation and infection. However, some species may act as potential pathogens. Elevated Clostridium species may indirectly damage the intestinal epithelial cells. Another symptom may include constipation.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics, treatment of any intestinal infections and dietary modification (reduce consumption of different fibres, such as inulin, oligofructose, arabinoxylan, guar gum and starch).

OXOLOBACTER FORMIGENES LOW:

PHYLUM: Proteobacterium

DESCRIPTION:

Oxalobacter formigenes is a Gram negative oxalate-degrading anaerobic bacterium. Oxolate is formed in the liver by amino acid catabolism as well as present in a wide range of foods including tea, coffee, chocolate and certain fruits and vegetables. High concentration of oxalate in the urine is related to the potential formation of calcium oxalate kidney stones. Oxolobacter Formigenes is the main known bacterial species involved in oxalate degradation in the gut and maintains oxalate homeostasis. Levels of O. Formigenes tends to decrease with age as well as with the use of antibiotics or other drugs. Low levels may be associated with calcium oxide stone formation, inflammatory bowel disease or Crohn's.

TREATMENT SUGGESTIONS:

Treatment options include probiotic treatment and low oxalate diet modification. Urinary oxalate levels may also need to be investigated.

Page 10 of 11 Complete Microbiome Map V2 Lab ID: 4017792 Patient Name: KARA MITCHELL Printed: 05/Sep/24 15:15



-.JAYNE ELDER SUITE 1/189 HARBOUR DRIVE COFFS HARBOUR NSW 2450

KARA MITCHELL 18-Mar-1988 Female

1 MORELIA WAY WOOMBAH NSW 2469

LAB ID : 4017792 UR NO. : 6644865 Collection Date : 26-Aug-2024 Received Date: 28-Aug-2024



4017792

The Four "R" Treatment Protocol

	Using a course of	ANTIMICROBIAL	Oil of oregano, berberine, caprylic acid
	antimicrobial, antibacterial, antiviral or anti parasitic therapiesin casswhere organisms are present. It may	ANTIBAC TERIAL	Liquorice, zinc camosine, mastic gum, tribulus, berberine, black walnut, caprylic acid, oil of oregano
REMOVE	also be necessary to remove offending foods, gluten, or	ANTIFUNGAL	Oil of oregano, caprylic acid, berberine, black walnut
	medication that may be acting as antagonists.	ANTIPARASTIC	Artemesia, black walnut, berberine, oil of oregano
	Consider testing IgG96 foods as a tool for removing offending foods.	ANTIVIRAL	Cat's claw, berberine, echinacea, vitamin C, vitamin D3, zinc, reishi mushrooms
		BIOFILM	Oil of oregano, protease
REPLACE	In cases of maldigestion or malabsorption, it may be necessary to restore proper digestion by supplementing with digestive enzymes.	DIGESTIVE SUPPORT	Betaine hydrochloride, tilactase, amylase, lipase, protease, apple cider vinegar, herbal bitters
ш	Recolonisation with healthy, beneficial bacteria.	PREBIOTICS	Sippery elm, pectin, larch arabinogalactans
RENOCULATE	Supplementation with probiotics, along with the use of prebiotics helps re-establish the proper microbial balance.	PROBIOTICS	Bifidobacterium animalis sup lactise, lactobacillus acidophilus, lactobacillus plantarum, lactobacillus casei, bifidobacterium breve, bifidobacterium bifidum, bifidobacterium longum, lactobacillus salivarius sep salivarius, lactobacillus paracasei, lactobacillus rhamnosus, Saccaromyces boulardii
BALANCE	Restore the integrity of the gut mucosa by giving support to healthy mucosal cells, as well as immune support. Address whole	INTESTINAL MUCOSA IMMUNE SUPPORT	Saccaromyces boulard ii, lauric acid
REPAIR & REBAL	body health and lifestyle factors so asto prevent future GI dysfunction.	INTESTINAL BARRIER REPAIR	L-Glutamine, aloe vera, liquorice, marshmallow root, okra, quercetin, slippery elm, zinc camosine, Saccaromycesboulardii, omega 3 essential fatty acids, B vitamins
REP/		SUPPORT CONSDERATION	Seep, diet, exercise, and stress management